News
-
Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity
11/6/2012
Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of beloranib.
-
Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (TMC435) And VX-135 For Treatment Of Hepatitis C
11/1/2012
Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).
-
Phase IIa Laquinimod Trial Results Show Positive Data For Potential Use In Active Crohn's Disease
10/22/2012
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn's disease (CD).
-
First Results From Phase 3 CANVAS Trial Show Canagliflozin As Add-on Therapy To Insulin Lowered Blood Sugar Levels In Patients With Type 2 Diabetes At An Elevated Risk For Cardiovascular Disease
10/2/2012
Janssen Research & Development, LLC (Janssen) today announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.
-
GNS Healthcare Collaborates With A Leading CRO To Enable More Efficient And Cost-Effective Drug Development
9/19/2012
GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Covance, one of the world's largest and most comprehensive contract research organizations.
-
Sanofi Pasteur Announces Publication In The Lancet Of World's First Efficacy Results For Its Dengue Vaccine Candidate
9/11/2012
Sanofi Pasteur, the vaccines division of Sanofi, announced recently the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.
-
Merck Announces New Phase III Data For Suvorexant, An Investigational Insomnia Medicine
9/10/2012
Merck, known as MSD outside the United States and Canada, recently announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.
-
Quotient And Pulmatrix Announce Completion Of Innovative COPD Proof-Of-Concept Clinical Program
9/4/2012
Quotient Clinical, a leading provider of specialist early stage drug development services, and Pulmatrix, a clinical stage biotechnology company creating novel inhaled therapeutics, recently announced the completion of an early clinical program to achieve proof-of-concept data in COPD patients for PUR118, Pulmatrix’s lead iCALM (inhaled dry powder cationic airway lining modulator) therapeutic.
-
Novartis QVA149 Phase III Study Meets Primary Endpoint In Reducing Exacerbations In COPD Patients, Filing In EU And Japan By End Of Year
8/30/2012
Novartis announced recently that the fifth QVA149 (indacaterol maleate / glycopyrronium bromide) Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri Breezhaler).
-
Lilly Stops Phase III Development Of Pomaglumetad Methionil For The Treatment Of Schizophrenia Based On Efficacy Results
8/29/2012
Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia.